mRNA-1647 Vaccine
Showing 1 - 25 of 8,830
Cytomegalovirus Infection Trial in Boston (mRNA-1647, Placebo)
Not yet recruiting
- Cytomegalovirus Infection
- mRNA-1647
- Placebo
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 4, 2023
Cytomegalovirus Infection Trial in North Hollywood, San Diego, Honolulu (mRNA-1647, Placebo)
Active, not recruiting
- Cytomegalovirus Infection
- mRNA-1647
- Placebo
-
North Hollywood, California
- +2 more
Dec 3, 2022
Cytomegalovirus Infection Trial in United States (mRNA-1647, Placebo)
Completed
- Cytomegalovirus Infection
- mRNA-1647
- Placebo
-
Sacramento, California
- +8 more
Jan 11, 2023
Cytomegalovirus Infection Trial in United States (mRNA-1647, Placebo)
Not yet recruiting
- Cytomegalovirus Infection
- mRNA-1647
- Placebo
-
Birmingham, Alabama
- +25 more
Nov 10, 2023
Cytomegalovirus Trial in Canada, United Kingdom, United States (mRNA-1647, Placebo)
Recruiting
- Cytomegalovirus
- mRNA-1647
- Placebo
-
La Mesa, California
- +60 more
Jan 12, 2023
Cytomegalovirus Infection Trial in Worldwide (mRNA-1647, Placebo)
Recruiting
- Cytomegalovirus Infection
- mRNA-1647
- Placebo
-
Phoenix, Arizona
- +165 more
Jan 13, 2023
Influenza, Human Trial (sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3)
Not yet recruiting
- Influenza, Human
- sa-mRNA vaccine Dose 1
- +4 more
- (no location specified)
Sep 7, 2023
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA
Not yet recruiting
- Adrenal Cortical Carcinoma
- +3 more
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
-
Shanghai, Shanghai, ChinaRuijin hospital, Shanghai Jiao-Tong University School of Medicin
Nov 19, 2023
SARS-CoV-2 Infection Trial in Hangzhou (Placebo, COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10
Recruiting
- SARS-CoV-2 Infection
- Placebo
- +4 more
-
Hangzhou, Zhejiang, ChinaShulan (Hangzhou) Hospital
Nov 7, 2023
SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus Trial in United States (mRNA-1273, mRNA-1010, mRNA-1345)
Recruiting
- SARS-CoV-2
- +3 more
- mRNA-1273
- +4 more
-
Hollywood, Florida
- +7 more
May 25, 2022
COVID-19 Trial in United States (mRNA-CR-04 vaccine 10µg, mRNA-CR-04 vaccine 30µg, mRNA-CR-04 vaccine 100µg)
Not yet recruiting
- COVID-19
- mRNA-CR-04 vaccine 10μg
- +3 more
-
San Diego, California
- +3 more
Aug 1, 2023
Seasonal Influenza Trial in United States (mRNA-1011.1, mRNA-1011.2, mRNA-1012.1)
Recruiting
- Seasonal Influenza
- mRNA-1011.1
- +5 more
-
Lakewood, California
- +21 more
Apr 12, 2023
Advanced Malignant Solid Tumors Trial (Neoantigen mRNA Personalised Cancer vaccine)
Not yet recruiting
- Advanced Malignant Solid Tumors
- Neoantigen mRNA Personalised Cancer vaccine
- (no location specified)
Jul 16, 2023
SARS-CoV-2 Infection Trial in Dengfeng, Zhengzhou (COVID-19 mRNA Vaccine (ZSVG-02-O), COVID-19 Vaccine (Vero Cell) ,Inactivated)
Recruiting
- SARS-CoV-2 Infection
- COVID-19 mRNA Vaccine (ZSVG-02-O)
- COVID-19 Vaccine (Vero Cell) ,Inactivated
-
Dengfeng, Henan, China
- +1 more
Nov 6, 2023
SARS-CoV-2 Trial in Chengdu (SARS-CoV-2 mRNA vaccine (RBMRNA), CoronaVac®)
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 mRNA vaccine (RBMRNA)
- CoronaVac®
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
Posto Perative Hepatocellular Carcinoma Trial (Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I
Not yet recruiting
- Posto Perative Hepatocellular Carcinoma
- Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
- (no location specified)
Feb 27, 2023
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
Vaccination; Infection, COVID-19 Trial (Comirnaty)
Not yet recruiting
- Vaccination; Infection
- COVID-19
- Comirnaty
- (no location specified)
Aug 4, 2023
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- Saline
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
Vaccine Reaction, COVID-19 Trial in Paris (Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta
Not yet recruiting
- Vaccine Reaction
- COVID-19
- Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)
- VidPrevtyn® Beta vaccine (Sanofi/GSK)
-
Paris, FranceCIC 1417 Cochin-Pasteur
Feb 28, 2023
Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine, Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine, Immune Response of
Not yet recruiting
- Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine
- +6 more
- ChulaCov19 BNA159 mRNA vaccine
-
Bangkok, Thailand
- +1 more
Nov 30, 2022
Influenza Trial in Iowa City (DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride,
Not yet recruiting
- Influenza
- DCVC H1 HA mRNA vaccine
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics - Department of Internal
Jul 6, 2023
COVID-19 Trial in Paris (Lymph node aspiration / Blood sampling)
Recruiting
- COVID-19
- Lymph node aspiration / Blood sampling
-
Paris, FranceGH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 19, 2023
SARS-CoV-2 Trial (SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
SARS-CoV-2 Trial (SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 variant mRNA vaccine low dose
- SARS-CoV-2 variant mRNA vaccine high dose
- (no location specified)
Oct 30, 2022